Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35675800/
1 Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON L8S 4L8, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada....
Relevance: Elevated liver de novo lipogenesis contributes to non-alcoholic steatohepatitis (NASH) and can be inhibited by targeting acetyl-CoA carboxylase (ACC). However, hypertriglyceridemia limits the use of pharmacological ACC inhibitors as a monotherapy. ATP-citrate lyase (ACLY) generates acetyl-CoA and oxaloacetate from citrate, but...
Medical complications of obesity: heightened importance in a COVID era - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35739488/
doi: 10.1186/s12245-022-00431-7. 1 Department of Emergency Medicine, University of Illinois at Chicago, Chicago, IL, USA. [email protected]. 2 Department of Emergency Medicine, University of Illinois at Chicago, Chicago, IL, USA. Free...
Conclusion: Obesity is an important modifiable risk factor. There is the need for healthcare providers to understand the medical complications associated with obesity to optimize patient care.
-
Amy Gonzales, MARK MALONE, MD, PA3yrWith or without Covid, addressing obesity will always be important in optimizing patient care as it is a risk factor to multitude other medical conditions.
-
Dr Hamid3yrInteresting article that reviews 8 primary diseases: type 2 diabetes, hypertension, dementia, non-alcoholic fatty liver disease, polycystic ovarian syndrome, dyslipidemia, cancer, and their manifestations in obese patients.
Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223034/
Lena Rutkowska, 1, * Kinga Sałacińska, 1 Dominik Salachna, 1 Paweł Matusik, 2 Iwona Pinkier, 1 Łukasz Kępczyński, 1 Małgorzata Piotrowicz, 1 Ewa Starostecka, 3 Andrzej Lewiński, 3, 4, *...
Conclusion: Our findings expand the spectrum of variants associated with the FH loci and will be of value in genetic counseling among patients with the disease.
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35666408/
Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical...
Conclusion/Relevance: Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering. Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular...
-
Dr Hamid3yrRelevant information on newest lipid-lowering medications.
Hypolipidemic activity of lactic acid bacteria: Adjunct therapy for potential probiotics
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269953
Background Individuals with hyperlipidemia are two times more likely to develop atherosclerotic cardiovascular disease (ASCVD) as opposed to those with controlled serum total cholesterol (TC) levels. Considering the documented adverse...
Conclusion: This study further supports the growing evidence regarding the antihyperlipidemic activity among probiotics, presenting them as a promising therapeutic approach for the management of hyperlipidemia.